Back

Time from first recorded clinical manifestation to diagnosis of transthyretin amyloid cardiomyopathy: a retrospective cohort study using US claims data

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: From genetics to AI: advancing risk prediction and diagnosis in heart failure Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Joshua Mitchell

Washington University, St Louis (United States of America)

5 More presentations in this session

Presentation thumbnail
Valvular heart disease and its association with mortality in advanced heart failure
Doctor K. Steiger (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Early clinical manifestations and time-to-diagnosis in patients with ATTR amyloidosis with mixed phenotype - results from the OverTTuRe study
Doctor L. Anderson (London, GB)
Abstract Slides Video
Presentation thumbnail
Evaluating machine learning-based data extraction for heart failure management: a step toward optimized therapy
Doctor J. Zmazek (Maribor, SI)
Abstract Slides Video
Presentation thumbnail
FINARM study versus FINE-HEART pooled analysis: comparative analysis of patients with heart failure and diabetic kidney disease
Mr E. Boada Lincango (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
Genome-wide association study of clinical outcomes in heart failure and Mendelian randomisation analysis of the impact of elevated body mass index on disease progression
Doctor N. Sunderland (Bristol, GB)
Abstract Slides Video

Access the full session

Session thumbnail
From genetics to AI: advancing risk prediction and diagnosis in heart failure

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
comparing diagnostic modalities and time to diagnosis in transthyretin amyloidosis: insights from a multi-ethnic asian registry
thumbnail
Congress Presentation
Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis
thumbnail
Congress Presentation
Changes in the diagnostic landscape of transthyretin amyloid cardiomyopathy (ATTR-CM): a comparison of tests ordered and test Intervals in 2020 Q4 and 2023 Q4

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources